Your browser doesn't support javascript.
loading
Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report.
Turcotte, Anna-Eve; Glass, William F; Lin, Jamie S; Burger, Jan A.
Affiliation
  • Turcotte AE; Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
  • Glass WF; Department of Pathology and Laboratory Medicine, University of Texas Health Science Center McGovern Medical School, Houston, TX, United States of America.
  • Lin JS; Division of Anatomic Pathology, Department of Pathology, The University of Virginia School of Medicine, Charlottesville, Virginia, United States of America.
  • Burger JA; Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Leuk Res Rep ; 20: 100377, 2023.
Article in En | MEDLINE | ID: mdl-37457553
ABSTRACT
Membranous nephropathy (MN) is an uncommon renal presentation in patients with chronic lymphocytic leukemia (CLL), and as such, there is no standard therapy for these patients. A few cases of MN in CLL have been described with varying success in MN treatment involving alkylating agents and fludarabine. Here we report the first case of MN in a patient with CLL treated with ibrutinib with complete renal response. This presentation underlines the importance of recognizing rare glomerular diseases that may occur with CLL and offers a new therapeutic avenue to the treatment of CLL-associated MN.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Leuk Res Rep Year: 2023 Document type: Article Affiliation country: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Leuk Res Rep Year: 2023 Document type: Article Affiliation country: Estados Unidos